SITE011-0035

SITE011 (ITA) › SITE011-0035

SITE011-0035

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2025-10-07

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-09 (study day 266); relationship: not assessed

moderate assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-12-30 (study day 256); relationship: not assessed

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 195); relationship: RELATED

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-06 (study day 171); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.